HER2/Neu: mechanisms of dimerization/oligomerization
2000 · Oncogene · 179 citations
https://doi.org/10.1038/sj.onc.1203967
A
Alan Berezov
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
45
Papers
2.2K
Citations
21
h-index
22
i10-index
Alan Berezov is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Monoclonal and Polyclonal Antibodies Research & HER2/EGFR in Cancer Research & T-cell and B-cell Immunology. The author has an h-index of 21, co-authored 39 publications.
Papers by this author
worksBIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
2008 · PubMed · 126 citations
Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies: Structure−Function Analysis
2001 · Journal of Medicinal Chemistry · 107 citations
https://doi.org/10.1021/jm000527m
Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics
2002 · Journal of Biological Chemistry · 92 citations
https://doi.org/10.1074/jbc.m202880200
HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand
2005 · DNA and Cell Biology · 32 citations
https://doi.org/10.1089/dna.2005.24.351
AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu
2006 · Oncogene · 32 citations
https://doi.org/10.1038/sj.onc.1209745
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat